Suggested remit: To appraise the clinical and cost effectiveness of epcoritamab within its marketing authorisation for treating relapsed or refractory diffuse large B-cell lymphoma when a stem cell transplant has failed or is unsuitable.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 4045

Provisional Schedule

Expected publication 06 March 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors AbbVie (epcoritamab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Blood Cancer UK
  Lymphoma Action
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Kite, a Gilead company (Axicabtagene ciloleucel) (confidentiality agreement signed, participating)
  Accord Healthcare (bendamustine, carboplatin, cisplatin, cytarabine, epirubicin, etoposide, gemcitabine, oxaliplatin) (confidentiality agreement not signed, not participating)
  Baxter Healthcare (cyclophosphamide, ifosfamide) (confidentiality agreement not signed, not participating)
  Celgene, a BMS company (lenalidomide) (confidentiality agreement not signed, not participating)
  Cheplapharm Arzneimittel GmbH (etoposide) (confidentiality agreement not signed, not participating)
  Consilient Health (bendamustine) (confidentiality agreement not signed, not participating)
  Dr Reddy’s Laboratories UK (bendamustine) (confidentiality agreement not signed, not participating)
  Hospira UK (carboplatin, cisplatin, cytarabine, gemcitabine, oxaliplatin, vincristine) (confidentiality agreement not signed, not participating)
  Incyte Biosciences (tafasitamab) (confidentiality agreement not signed, not participating)
  Medac GmBH (epirubicin, etoposide, lomustine, oxaliplatin) (confidentiality agreement not signed, not participating)
  Napp Pharmaceuticals (rituximab) (confidentiality agreement not signed, not participating)
  Pfizer (cytarabine, epirubicin, rituximab) (confidentiality agreement not signed, not participating)
  Roche Products (polatuzumab, rituximab) (confidentiality agreement not signed, not participating)
  Sandoz (cisplatin, rituximab) (confidentiality agreement not signed, not participating)
  Seacross pharmaceuticals (bendamustine, epirubicin, oxaliplatin) (confidentiality agreement not signed, not participating)
  Servier Laboratories (pixantrone) (confidentiality agreement not signed, not participating)
  Sun Pharmaceuticals (gemcitabine, oxaliplatin) (confidentiality agreement not signed, not participating)
  Zentiva (bendamustine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
01 February 2024 - 15 February 2024 Final draft guidance
12 December 2023 Committee meeting: 2
01 November 2023 - 21 November 2023 Draft guidance
10 October 2023 Committee meeting
10 February 2023 Invitation to participate
17 November 2022 - 15 December 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 November 2022 In progress. Scoping commenced
25 November 2021 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual